Background: IGF2BP1 Biology and Research Relevance

IGF2BP1 (Insulin-like Growth Factor 2 mRNA-Binding Protein 1), also known as IMP1, CRD-BP, or ZBP1, is a member of the IGF2BP family of RNA-binding proteins. It contains two RNA-recognition motifs (RRM) and four K-homology (KH) domains that mediate sequence-specific binding to target mRNAs.

IGF2BP1 regulates the stability, localization, and translation of key oncogenic transcripts including MYC, ACTB, and CD44 mRNAs. It is overexpressed in a wide range of human cancers and has been identified as an m6A (N6-methyladenosine) reader protein, linking it to the epitranscriptomic regulation of gene expression.

Recombinant Human IGF2BP1 Protein (rp374575) is suitable for use in biochemical and cell-free assays exploring RNA–protein interactions, post-transcriptional regulatory mechanisms, and as a tool antigen for antibody validation.

Reagents, Equipment, and Safety Precautions

Required reagents:

• Recombinant Human IGF2BP1 Protein (rp374575)
• Sterile, nuclease-free deionized water or PBS (pH 7.4) for reconstitution
• Carrier protein (e.g., 0.1% BSA) if required for long-term stability at low concentrations
• Appropriate assay buffer compatible with downstream application (e.g., EMSA buffer, RIP lysis buffer)

Equipment:

• Microcentrifuge and low-protein-binding microtubes
• Ice bucket and dry ice for cold-chain handling
• -80°C freezer for long-term storage
• Spectrophotometer or fluorometer for protein quantification (BCA or Bradford assay)

Safety: Handle according to standard laboratory biosafety procedures for recombinant proteins. Consult the Safety Data Sheet (SDS) before use. Wear appropriate PPE including gloves and lab coat.

Step-by-Step Reconstitution and Handling Protocol

Step 1 – Thawing: Remove the vial from -80°C storage and allow it to thaw slowly on ice (approximately 10–15 minutes). Do not thaw at room temperature or by heating, as this can lead to protein aggregation and loss of activity.

Step 2 – Brief centrifugation: Pulse-centrifuge the vial (1,000–2,000 × g, 30 seconds) to collect the lyophilized cake or liquid concentrate at the bottom of the tube.

Step 3 – Reconstitution (if lyophilized): Add the recommended volume of sterile nuclease-free water or PBS (pH 7.4) as stated on the product datasheet. Gently pipette up and down to dissolve; do not vortex. Allow 5–10 minutes at room temperature with gentle swirling if needed.

Step 4 – Protein quantification: Measure protein concentration using a BCA or Bradford assay. Compare against the certificate of analysis (CoA) value to confirm recovery.

Step 5 – Aliquoting: Prepare single-use aliquots at the desired working concentration to avoid repeated freeze-thaw cycles, which degrade protein integrity and RNA-binding activity.

Step 6 – Storage: Store aliquots at -80°C. For short-term use within 1 week, aliquots may be kept at -20°C. Adding a carrier protein such as 0.1% BSA is recommended for dilute working stocks (<10 µg/mL).

Note: Always refer to the specific product datasheet for lot-specific reconstitution volumes, storage buffers, and concentration values.

Experimental Applications and Assay Guidance

Recombinant Human IGF2BP1 Protein is suitable for the following research applications:

• Electrophoretic Mobility Shift Assay (EMSA): Use purified IGF2BP1 to assess direct binding to RNA oligonucleotides harboring m6A modifications or IGF2BP1 consensus motifs. Titrate protein from approximately 50 nM to 2 µM against a fixed concentration of labeled RNA probe.
• RNA Immunoprecipitation (RIP): IGF2BP1 recombinant protein can serve as a positive control for RIP assays or for in vitro RIP optimization.
• Protein–Protein Interaction Studies: Use in co-immunoprecipitation or pull-down assays to map IGF2BP1 interaction partners within the mRNP complex.
• Antibody Validation: Use as a positive control antigen in Western blot (expected molecular weight approximately 63 kDa) and ELISA-based antibody specificity validation.
• In Vitro Functional Assays: Assess the effect of IGF2BP1 on mRNA stability or translation in cell-free systems using reconstituted translation extracts.

Note: Optimal protein concentrations and buffer conditions should be empirically determined for each specific assay format and downstream detection system.

Troubleshooting and Quality Control

Problem: Low or no activity in RNA-binding assay
Possible causes: protein aggregation due to improper thawing; repeated freeze-thaw cycles; incompatible buffer salt or pH. Solutions: thaw on ice; use fresh single-use aliquots; verify buffer conditions match those in the datasheet.

Problem: Unexpected molecular weight on SDS-PAGE
IGF2BP1 runs at approximately 63 kDa under denaturing conditions. Post-translational modifications or tags may shift apparent MW. Confirm with the CoA and expected tag information on the datasheet.

Problem: Protein precipitation after reconstitution
Centrifuge at 10,000–14,000 × g for 5 minutes at 4°C to remove aggregates before use. Consider adding a non-ionic detergent (e.g., 0.01% Tween-20) if aggregation persists, and confirm this is compatible with your downstream assay.

Quality control checks recommended before each experiment:

• Confirm protein concentration via BCA/Bradford assay
• Run an SDS-PAGE to verify purity and integrity
• Perform a pilot EMSA or dot-blot RNA-binding experiment to confirm functional activity